single-agent atezolizumab supported for some cisplatin-ineligible muc patients | matthew galsky
Published 3 years ago • 85 plays • Length 6:13Download video MP4
Download video MP3
Similar videos
-
4:15
ev-201: enfortumab an option for cisplatin-ineligible advanced uc | arjun balar
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
3:45
treatment options for cisplatin-ineligible patients with advanced bladder cancer
-
4:50
cisplatin-ineligible treatment options for advanced bladder cancer - bladder cancer video library
-
5:03
atezolizumab with ebrt for bladder preservation in mibc
-
3:23
flanged fixation secures iol haptics within the sclera
-
5:35
cisplatin mnemonic for nclex | nursing pharmacology
-
26:20
management of non-muscle invasive bladder cancer
-
13:25
treatment considerations for patients with cisplatin-ineligible bladder cancer
-
1:03:24
bladder cancer: understanding immune-, targeted-, and antibody-based models for patient care
-
1:45
case 2: i/o therapy for cisplatin-ineligible bladder cancer
-
4:26
the evolution of first line therapy in cisplatin-ineligible patients - bladder cancer video library
-
4:06
enzalutamide, gemcitabine, and cisplatin for metastatic bladder cancer
-
3:00
atezolizumab limits disease progression for metastatic urothelial bladder cancer
-
1:10
dr. steinberg on the fda approval of atezolizumab in bladder cancer
-
1:59
dr. matthew galsky on a post-treatment nomogram in urothelial cancer
-
7:05
the fda approval of atezolizumab in bladder cancer
-
32:26
07 immunotherapy for bladder cancer what is standard and what is the future prof m galsky
-
4:58
the human urinary / renal system
-
6:49
fda approval of atezolizumab for advanced bladder cancer
-
52:35
using the case study of atezolizumab development to rethink early phase oncology trial design